Novartis accredited with global ‘CEO Cancer Gold Standard’ for outstanding efforts in cancer prevention and treatment

Joseph Jiminez

Novartis has earned global CEO Cancer Gold Standard accreditation by the non-profit organisation CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognises the company’s efforts to provide support to Novartis associates in the prevention, diagnosis and treatment of cancer.

“At Novartis, we believe that everyone should have access to early screening programmes and innovative therapies,” said Joseph Jimenez, Chief Executive Officer, Novartis. “Our efforts for our associates, which are recognised by this designation, are an extension of our goal to redefine cancer for all patients.”

Novartis is passionate about the discovery and development of innovative medicines to help provide a broad range of new therapies and practical solutions to advance care of patients. The company’s research is driven by a distinctive scientific and clinical strategy focusing on unmet medical needs and knowledge of disease pathways. The Novartis research strategy leverages biomarkers and targeted drug development focused on individual patients. The company’s extensive portfolio of access-to-treatment projects adapts to patients’ needs, products, collaborators and countries.

Novartis first achieved CEO Cancer Gold Standard designation in the US, and quickly extended these resources around the world. Since then, the company has offered programmes such as: adding preventive health services in Portugal; a year-long plan on health promotion and its benefits in the Philippines; regular screenings for colon and breast cancers in Japan and Brazil.

EP News Bureau – Mumbai